** ASX-listed shares of Mesoblast MSB.AX jump as much as 8.8% to A$1.800; marks biggest intraday pct gain since June 4
** MSB hits highest since June 19
** Stock biggest gainer on S&P/ASX 200 index .AXJO; set for sixth straight session of gains
** Cell-therapy tech firm and U.S. FDA align on key items for Biologics License Application for its therapy product, Revascor
** Revascor is being developed to treat advanced, end-stage chronic heart failure
** Co intends to apply for accelerated FDA approval by 2025-end
** MSB last up 7.3%, trimming YTD losses to 45%
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.